No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease.

Abstract:

:We recently showed an association between the FCGR3A V/F polymorphism and the biological response [assessed on the basis of a C-reactive protein (CRP) concentration decrease] to infliximab in Crohn's disease. The CRP and FCGR3A genes are located on the same 1q23 locus. The present study aimed: (i) to exclude a linkage disequilibrium (LD) between the two genes and (ii) to study the association between CRP polymorphisms and the response to infliximab, particularly the decrease in CRP after treatment, in Crohn's disease patients. FCGR3A (V/F) polymorphism and three CRP polymorphisms (-717G/A, 1444C/T, CRP 4A/G) were determined in 206 healthy blood donors and 189 Crohn's disease patients who had received infliximab for either refractory luminal or fistulizing Crohn's disease. Clinical response was defined as complete, partial or absent according to the same definition as in controlled trials. The biological response was defined on the basis of CRP decrease. There was no LD between CRP and FCGR3A in healthy donors or Crohn's disease patients. CRP polymorphisms had no impact on CRP decrease after infliximab. The proportions of Crohn's disease having a positive clinical or biological response were not statistically different among the various genotypes of CRP polymorphisms. There was no LD between CRP and FCGR3A polymorphisms. CRP polymorphisms were not associated with the response to infliximab in Crohn's disease.

journal_name

Pharmacogenet Genomics

authors

Willot S,Vermeire S,Ohresser M,Rutgeerts P,Paintaud G,Belaiche J,De Vos M,Van Gossum A,Franchimont D,Colombel JF,Watier H,Louis E

doi

10.1097/01.fpc.0000182776.57437.d8

keywords:

subject

Has Abstract

pub_date

2006-01-01 00:00:00

pages

37-42

issue

1

eissn

1744-6872

issn

1744-6880

pii

01213011-200601000-00005

journal_volume

16

pub_type

杂志文章
  • Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers.

    abstract:AIM:A finite number of variants in the OPRM1, COMT, MC1R, ABCB1 and CYP2D6 genes has been identified to significantly modulate the effects of opioids in controlled homogenous settings. We analyzed the imprint of these variants in opioid therapy in a highly variable cohort of pain patients treated in outpatient units to...

    journal_title:Pharmacogenetics and genomics

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1097/fpc.0b013e32832b89da

    authors: Lötsch J,von Hentig N,Freynhagen R,Griessinger N,Zimmermann M,Doehring A,Rohrbacher M,Sittl R,Geisslinger G

    更新日期:2009-06-01 00:00:00

  • Characterization of intron-1 haplotypes of the G protein beta 4 subunit gene--association with survival and progression in patients with urothelial bladder carcinoma.

    abstract:PURPOSE:Polymorphisms in genes encoding subunits of heterotrimeric G proteins have been repeatedly associated with various cancers. As G beta gamma signaling is presumed to be involved in proliferation and invasion processes, we analyzed genetic variations in regulatory regions of GNB4, which encodes the G beta 4 subun...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e3283117d79

    authors: Riemann K,Struwe H,Eisenhardt A,Obermaier B,Schmid KW,Siffert W

    更新日期:2008-11-01 00:00:00

  • Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics.

    abstract:OBJECTIVE:Exemestane is a third-generation aromatase inhibitor used in the treatment of breast cancer in postmenopausal women. Reduction to form 17-dihydroexemestane and subsequent glucuronidation to exemestane-17-O-glucuronide is a major pathway for exemestane metabolism. The goal of this study was to analyze 17-dihyd...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e32833b04af

    authors: Sun D,Chen G,Dellinger RW,Sharma AK,Lazarus P

    更新日期:2010-10-01 00:00:00

  • Combined effects of hepatocyte nuclear factor 4α and constitutive androstane receptor on stable warfarin doses.

    abstract::A possible association between the combination of genetic variations in hepatocyte nuclear factor 4α (HNF4α) and constitutive androstane receptor (CAR) and the stable doses of warfarin was examined in patients from the Ewha-Severance Treatment (EAST) Group of Warfarin. Around 42.5% of the overall interindividual varia...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000103

    authors: Moon JY,Lee KE,Chang BC,Jeong E,Jeong H,Gwak HS

    更新日期:2015-01-01 00:00:00

  • Effect of folic acid intervention on the change of serum folate level in hypertensive Chinese adults: do methylenetetrahydrofolate reductase and methionine synthase gene polymorphisms affect therapeutic responses?

    abstract:OBJECTIVES:To assess the influence of individual methylenetetrahydrofolate reductase (MTHFR) C677T and methionine synthase A2756G polymorphisms on the change of serum folate concentration in response to different dosages and durations of folic acid (FA) supplementation in hypertensive Chinese adults. METHODS:A total o...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/FPC.0b013e32834ac5e8

    authors: Qin X,Li J,Cui Y,Liu Z,Zhao Z,Ge J,Guan D,Hu J,Wang Y,Zhang F,Xu X,Wang X,Xu X,Huo Y

    更新日期:2012-06-01 00:00:00

  • Functional consequences of nonsynonymous single nucleotide polymorphisms in the CB2 cannabinoid receptor.

    abstract:OBJECTIVE:To test the hypothesis that the two nonsynonymous single nucleotide polymorphisms at the CB2 cannabinoid receptor gene may have functional consequences on human CB2. METHODS:Q63R, H316Y, and Q63R/H316 mutations were made in recombinant human CB2 by the method of site-directed mutagenesis. After these mutant ...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e3283367c6b

    authors: Carrasquer A,Nebane NM,Williams WM,Song ZH

    更新日期:2010-03-01 00:00:00

  • Common ABCB1 polymorphisms are not associated with multidrug resistance in epilepsy using a gene-wide tagging approach.

    abstract::P-glycoprotein, the product of the ABCB1 gene, is a proposed mechanism of pharmacoresistance in epilepsy. Previous attempts to correlate the ABCB1 C3435T SNP, or a three-SNP haplotype containing C3435T with epilepsy pharmacoresistance have produced discordant findings. We analysed these single nucleotide polymorphisms...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章,meta分析

    doi:10.1097/01.fpc.0000230408.23146.b1

    authors: Leschziner GD,Andrew T,Leach JP,Chadwick D,Coffey AJ,Balding DJ,Bentley DR,Pirmohamed M,Johnson MR

    更新日期:2007-03-01 00:00:00

  • CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case-control study.

    abstract:OBJECTIVE:The aim of this study was to assess whether the CYP2C9*2 and/or *3 variants might modify the risk for NSAID-related upper gastrointestinal bleeding (UGIB) in NSAID users. PATIENTS AND METHODS:We conducted a multicenter, case-control study in which cases were patients aged more than 18 years with a diagnosis ...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000186

    authors: Figueiras A,Estany-Gestal A,Aguirre C,Ruiz B,Vidal X,Carvajal A,Salado I,Salgado-Barreira A,Rodella L,Moretti U,Ibáñez L,EMPHOGEN group.

    更新日期:2016-02-01 00:00:00

  • Association of the UGT1A1-53(TA)n polymorphism with L-thyroxine doses required for thyrotropin suppression in patients with differentiated thyroid cancer.

    abstract::There is a considerable interindividual variation in L-thyroxine [3,5,3',5'-tetraiodo-l-thyronine (T4)] dose required for thyrotropin (thyroid-stimulating hormone) suppression in patients with differentiated thyroid cancer. To investigate whether uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)-mediated T4 gl...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e3283448d19

    authors: Vargens DD,Neves RR,Bulzico DA,Ojopi EB,Meirelles RM,Pessoa CN,Prado CM,Gonçalves PA,Leal VL,Suarez-Kurtz G

    更新日期:2011-06-01 00:00:00

  • Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid.

    abstract:OBJECTIVE:The effects of various polymorphisms in cytochrome P450 (CYP) enzyme and transporter genes on the pharmacokinetics (PK) of simvastatin were evaluated in healthy Korean men. METHODS:Plasma concentration data for simvastatin and simvastatin acid were pooled from four phase I studies comprising 133 participants...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/FPC.0000000000000176

    authors: Choi HY,Bae KS,Cho SH,Ghim JL,Choe S,Jung JA,Jin SJ,Kim HS,Lim HS

    更新日期:2015-12-01 00:00:00

  • The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping.

    abstract:BACKGROUND/OBJECTIVES:The polymorphic hepatic enzyme CYP2C19 catalyzes the metabolism of clinically important drugs such as clopidogrel, proton-pump inhibitors, and others and clinical pharmacogenetic testing for clopidogrel is increasingly common. The CYP2C19*10 single-nucleotide polymorphism (SNP) is located 1 bp ups...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000068

    authors: Langaee TY,Zhu HJ,Wang X,El Rouby N,Markowitz JS,Goldstein JA,Johnson JA

    更新日期:2014-08-01 00:00:00

  • CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population.

    abstract::The genetically polymorphic cytochrome P450 2C9 (CYP2C9) metabolizes many important drugs. Among them, phenytoin has been used as a probe to determine CYP2C9 phenotype by measuring the urinary excretion of its major metabolite, S-enantiomer of 5-(4-hydroxyphenyl)-5-phenylhydantoin (p-HPPH). Phenytoin pharmacokinetic i...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/01.fpc.0000174787.92861.91

    authors: Allabi AC,Gala JL,Horsmans Y

    更新日期:2005-11-01 00:00:00

  • Association of Cullin1 haplotype variants with rheumatoid arthritis and response to methotrexate.

    abstract::Aberrations in ubiquitin pathway have been implicated in many diseases and drug response. In a previous study on rheumatoid arthritis (RA) in Japanese population, significant association of Cullin1 gene (CUL1), an ubiquitin E3 ligase, was observed. CUL1 also mediates degradation of IκBα and p27, levels of which has be...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e3283492af7

    authors: Negi S,Kumar A,Thelma BK,Juyal RC

    更新日期:2011-09-01 00:00:00

  • Strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals.

    abstract:OBJECTIVE:The effects of CYP2C9*1/*3 and *3/*3 genotypes on the pharmacokinetics and pharmacodynamics of meloxicam were evaluated in healthy Korean subjects. METHODS:After oral administration of 15 mg meloxicam, the plasma concentrations of meloxicam were assessed in 11 CYP2C9*1/*1 individuals, eight CYP2C9*1/*3 indiv...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000025

    authors: Lee HI,Bae JW,Choi CI,Lee YJ,Byeon JY,Jang CG,Lee SY

    更新日期:2014-02-01 00:00:00

  • The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma.

    abstract:OBJECTIVE:Identification of biomarkers that could predict gemcitabine efficacy and toxicity is a key issue in the development of individualized therapy. The aim of our study was to evaluate the influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma (MM). METHODS:In ...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e32834e3572

    authors: Erčulj N,Kovač V,Hmeljak J,Franko A,Dodič-Fikfak M,Dolžan V

    更新日期:2012-01-01 00:00:00

  • A comprehensive contribution of genes for aryl hydrocarbon receptor signaling pathway to hypertension susceptibility.

    abstract:OBJECTIVE:The present study was designed to investigate whether genetic polymorphisms of the aryl hydrocarbon receptor (AHR) signaling pathway are involved in the molecular basis of essential hypertension (EH). METHODS:A total of 2160 unrelated Russian individuals comprising 1341 EH patients and 819 healthy controls w...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000261

    authors: Polonikov AV,Bushueva OY,Bulgakova IV,Freidin MB,Churnosov MI,Solodilova MA,Shvetsov YD,Ivanov VP

    更新日期:2017-02-01 00:00:00

  • Influence of CYP2C9 genetic variants on gastrointestinal bleeding associated with nonsteroidal anti-inflammatory drugs: a systematic critical review.

    abstract::The existence of genetic polymorphisms in metabolizing enzymes can be regarded as one of the principal causes of interindividual variation in response to drugs and adverse reactions. In the case of enzyme CYP2C9, the presence of genetic coding variants could be considered a risk factor for suffering from gastrointesti...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章,评审

    doi:10.1097/FPC.0b013e328346d2bb

    authors: Estany-Gestal A,Salgado-Barreira A,Sánchez-Diz P,Figueiras A

    更新日期:2011-07-01 00:00:00

  • Three haplotypes associated with CYP2A6 phenotypes in Caucasians.

    abstract::The human cytochrome P450 2A6 (CYP2A6) enzyme metabolizes several xenobiotic compounds of clinical or toxicological importance. We aimed to identify genetic variants and major CYP2A6 haplotypes associated with CYP2A6 phenotypic variation. CYP2A6 mRNA level, protein level, activity and haplotypes were determined in Cau...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/01.fpc.0000171517.22258.f1

    authors: Haberl M,Anwald B,Klein K,Weil R,Fuss C,Gepdiremen A,Zanger UM,Meyer UA,Wojnowski L

    更新日期:2005-09-01 00:00:00

  • Increased CYP3A4 copy number in TONG/HCC cells but not in DNA from other humans.

    abstract::Two recent screens for copy-number variations in the entire human genome found 12.4 gene copy number variations per person, including 2.5% of individuals with gains between 7q21.1 and 7q22.1, the chromosomal location of CYP3A4. CYP3A4 is involved in the metabolism of approximately 50% of all drugs, including many canc...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/01.fpc.0000194421.35641.70

    authors: Lamba JK,Chen X,Lan LB,Kim JW,Wei Wang X,Relling MV,Kazuto Y,Watkins PB,Strom S,Sun D,Schuetz JD,Schuetz EG

    更新日期:2006-06-01 00:00:00

  • MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression.

    abstract:BACKGROUND:Despite the enormous success of imatinib in chronic myeloid leukemia (CML), therapy resistance has emerged in a significant proportion of patients, partly because of the overexpression of ABC efflux transporters. METHODS:Using an array comprising 667 miRNAs, we investigated whether the expression of microRN...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e328350012b

    authors: Turrini E,Haenisch S,Laechelt S,Diewock T,Bruhn O,Cascorbi I

    更新日期:2012-03-01 00:00:00

  • Deciphering ADME genetic data using an automated haplotype approach.

    abstract:OBJECTIVE:To investigate the utility of statistical tools in translating Affymetrix Drug Metabolizing Enzyme and Transporter (DMET) Assay single-nucleotide polymorphisms (SNPs) into common consensus star alleles. METHODS:DMET SNP data from clinical trials in different ethnicities were pooled for analyses. Three differ...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000047

    authors: Guo Y,Farmen MW,Jin Y,Lee HY,Penny MA,Hillgren KM,Fossceco SL

    更新日期:2014-06-01 00:00:00

  • A novel promoter polymorphism in the human gene GNAS affects binding of transcription factor upstream stimulatory factor 1, Galphas protein expression and body weight regulation.

    abstract:OBJECTIVES:Body weight regulation is under complex control involving the central nervous system and peripheral pathways. The beta-adrenoceptor Galphas protein system plays an important role in heart rate regulation and lipid mobilization suggesting a key role for the stimulatory G protein Galphas in body weight regulat...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/FPC.0b013e3282f49964

    authors: Frey UH,Hauner H,Jöckel KH,Manthey I,Brockmeyer N,Siffert W

    更新日期:2008-02-01 00:00:00

  • Polymorphisms of vitamin D receptor gene protect against the risk of head and neck cancer.

    abstract::Vitamin D has potent anti-tumour properties. Calcitriol [1,25(OH)2D3], the hormonal derivative of vitamin D3, is an antiproliferative and prodifferentiation factor for several cell types, including human squamous cells of the head and neck. Several polymorphisms of the vitamin D receptor (VDR) gene have been described...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/01213011-200503000-00004

    authors: Liu Z,Calderon JI,Zhang Z,Sturgis EM,Spitz MR,Wei Q

    更新日期:2005-03-01 00:00:00

  • Evaluation of polymorphisms in the sulfonamide detoxification genes NAT2, CYB5A, and CYB5R3 in patients with sulfonamide hypersensitivity.

    abstract:OBJECTIVE:To determine whether polymorphisms in the sulfonamide detoxification genes, CYB5A (encoding cytochrome b(5)), CYB5R3 (encoding cytochrome b(5) reductase), or NAT2 (encoding N-acetyltransferase 2) were over-represented in patients with delayed sulfonamide drug hypersensitivity, compared with control patients w...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e328357a735

    authors: Sacco JC,Abouraya M,Motsinger-Reif A,Yale SH,McCarty CA,Trepanier LA

    更新日期:2012-10-01 00:00:00

  • Association between two key SNPs on chromosome 12p13 and ischemic stroke in Chinese Han population.

    abstract:OBJECTIVE:Genome-wide single nucleotide polymorphism (SNP) association studies recently identified two SNPs (rs11833579 and rs12425791) on chromosome 12p13 that are associated with ischemic stroke (IS) in Caucasian or Black persons from America and the Netherlands. Our aim was to determine whether these SNPs were assoc...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0b013e32834911d0

    authors: Tong Y,Zhang Y,Zhang R,Geng Y,Lin L,Wang Z,Liu J,Li X,Cao Z,Xu J,Chai Y,Fan H,Hu FB,Lu Z,Cheng J

    更新日期:2011-09-01 00:00:00

  • Methods and implementation of a pediatric asthma pharmacogenomic study in the emergency department setting.

    abstract:OBJECTIVES:The emergency department (ED) is a challenging setting to conduct pharmacogenomic studies and integrate that data into fast-paced and potentially life-saving treatment decisions. Therefore, our objective is to present the methods and feasibility of a pilot pharmacogenomic study set in the ED that measured pe...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000414

    authors: Fishe JN,Higley RK,Casey D,Hogans L,Wylie TW,Hendry PL,Henson M,Bertrand A,Blake KV

    更新日期:2020-12-01 00:00:00

  • Pharmacogeomic implications of population diversity in Latin America: TPMT and NUDT15 polymorphisms and thiopurine dosing.

    abstract::TPMT and NUDT15 polymorphisms are major determinants of tolerance to thiopurine drugs used in leukemias and nonmalignant immunologic disorders. We adopted an extreme discordant phenotype approach to explore the impact of Native American versus European ancestry on the distribution of TPMT and NUDT15 polymorphisms, and...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000388

    authors: Suarez-Kurtz G,Araújo GS,de Sousa SJ

    更新日期:2020-01-01 00:00:00

  • Novel procedure with improved resolution and specificity for amplification and differentiation of variants of the gene encoding carboxylesterase 1.

    abstract::Carboxylesterase 1 (CES1) is implicated in the metabolism of several commonly used drugs and other xenobiotics. The gene encoding this enzyme, CES1, is duplicated in some individuals. The original gene copy is called CES1A1. The duplicated version, CES1A2, is a hybrid of CES1A1 and the CES1-related pseudogene, CES1P1....

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/FPC.0000000000000267

    authors: Bjerre D,Rasmussen HB,INDICES Consortium.

    更新日期:2017-04-01 00:00:00

  • Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism.

    abstract:BACKGROUND:Organic anion transporting polypeptides (OATPs) are emerging as major determinants of pharmacokinetics for numerous drugs, with the 1B1 isoform-mediating hepatic uptake. The 521 T>C polymorphism has been correlated earlier with higher plasma concentrations of several drugs and the aim of this study was to de...

    journal_title:Pharmacogenetics and genomics

    pub_type: 临床试验,杂志文章

    doi:10.1097/FPC.0b013e3283402efb

    authors: Siccardi M,D'Avolio A,Nozza S,Simiele M,Baietto L,Stefani FR,Moss D,Kwan WS,Castagna A,Lazzarin A,Calcagno A,Bonora S,Back D,Di Perri G,Owen A

    更新日期:2010-12-01 00:00:00

  • Experimental validation of data mined single nucleotide polymorphisms from several databases and consecutive dbSNP builds.

    abstract::Rapid development in the annotation of human genetic variation has increased the numbers of single nucleotide polymorphisms (SNPs) in candidate genes by several orders of magnitude. The selection of both useful target SNPs for disease-gene association studies and SNPs associated with the treatment response is therefor...

    journal_title:Pharmacogenetics and genomics

    pub_type: 杂志文章

    doi:10.1097/01.fpc.0000194422.12770.fb

    authors: Edvardsen H,Irene Grenaker Alnaes G,Tsalenko A,Mulcahy T,Yuryev A,Lindersson M,Lien S,Omholt S,Syvänen AC,Børresen-Dale AL,Kristensen VN

    更新日期:2006-03-01 00:00:00